| PRP | Platelet-Rich Plasma |
| PPP | Platelet-poor plasma |
| A-PRP | Autologous-Non-activated Platelet-Rich Plasma |
| AA-PRP | Autologous-Activated Platelet-Rich-Plasma |
| GFs | Growth Factors |
| VEGF | Vascular endothelial Growth factors |
| PDGF | Platelet Derived Growth factors |
| IGF-1 | Insulin like Growth factor-1 |
| TGF-ß | Transforming growth factor-beta |
| EGF | Epidermal growth factor |
| DPCs | Dermal papilla cells |
| EC | European Committee |
| CAT | Committee for Advanced treatments; |
| GMP | Good Manufacturing Practices |
| GCP | Good Clinical Practices |
| ECM | Extracellular matrix |
| SVFs | Stromal vascular Fraction Cells |
| AD-MSCs | Adipose-derived Mesenchymal Stem Cells |
| RPM | Right per minute |
| PRISMA-P | Preferred Reporting for Items for Systematic Reviews and Meta-Analyses-Protocols |
| CTGF | Connecting tissue growth factor |
| EBM | Evidence Based Medicine |
| MRI | Magnetic resonance imaging |
| CT | Computed Tomography |
| HA | Hyaluronic acid |
| OCEBM | Oxford Centre for Evidence-Based Medicine |
| WOMAC | Western Ontario and McMaster University’s Osteoarthritis Index scores |
| WBCs | White blood cells |
| DMEM | Dulbecco’s Modified Eagle Medium |
| FBS | Fetal Bovine serum |
| PLT | Platelets |